Polaryx Therapeutics is a clinical-stage biotechnology company advancing a multimodal pipeline of small-molecule and gene therapies for rare pediatric lysosomal storage disorders. Its lead program, PLX-200, is a proprietary oral small molecule being advanced through the SOTERIA Phase 2 basket trial across multiple indications. Pulse 2.0 interviewed Polaryx Therapeutics CEO Alex Yang to learn more.
Alex Yang’s Background
When asked about his background, Yang shared:
I have more than 25 years of experience spanning law, finance, private equity, and biopharmaceutical leadership. I have served as Chair of Polaryx since June 2021 and Chief Executive Officer since March 2023, and I am also the founder and CEO of Mstone Partners, a life science and healthcare-focused incubation platform.
Since 2016, I have held senior management and board chair roles across multiple biopharmaceutical companies, focusing on governance, capital strategy, and value creation in rare disease development. Earlier in my career, I was a managing partner at Kim & Chang and a partner at Ernst & Young in Hong Kong, where I led regional financial services initiatives. I also worked at Morgan Stanley in Hong Kong in Asia Private Equity and as in-house counsel, advising on buyouts, growth capital, and infrastructure transactions.
I earned both my J.D. and LL.M. from New York University School of Law and hold an undergraduate degree in Economics from Binghamton University. This blend of legal, capital markets, and governance experience shapes my approach to building Polaryx as a disciplined, science-driven rare disease company.
How Polaryx Started
When asked how the idea for the company came together, Yang explained:
Polaryx was founded to address a critical unmet need in rare, pediatric lysosomal storage disorders, devastating inherited metabolic diseases that lead to progressive neurological decline, organ damage, and often early mortality.
Despite advances in rare disease medicine, many of these conditions still lack disease-modifying therapies, and existing treatments can require invasive administration methods that place significant burdens on children and their families.
We saw an opportunity to build a multimodal platform combining small molecule and gene therapy approaches, targeting both the genetic drivers and downstream pathological mechanisms of lysosomal storage disorders. Our goal is to develop disease-modifying treatments that are not only effective but also patient-friendly, particularly important in pediatric populations.
Core Products And Pipeline
When asked about the company’s core products and features, Yang detailed:
Polaryx is a clinical-stage biotechnology company advancing a multimodal pipeline of small-molecule and gene therapies designed to treat rare pediatric lysosomal storage disorders. Our strategy is centered on developing disease-modifying treatments that address both the underlying genetic drivers and the downstream pathological effects of these devastating conditions.
Our lead program, PLX-200, is a proprietary oral small molecule candidate with multiple mechanisms of action. In preclinical models, PLX-200 has demonstrated meaningful improvements across several key measures, including reduction of lysosomal storage material, decreased neuroinflammation, preservation of neuronal function, improved locomotor outcomes, and extended survival.
A key differentiator of PLX-200 is its liquid oral formulation, which is designed to enhance bioavailability, dosing precision, and patient compliance, particularly important in pediatric populations. This contrasts with certain currently approved therapies that require invasive administration methods, underscoring the need for more patient-friendly treatment options.
We are advancing PLX-200 through SOTERIA, a flexible open-label Phase 2 basket trial evaluating multiple lysosomal storage disorder indications, including CLN2, CLN3, Krabbe disease, and Sandhoff disease. This basket-trial design allows us to efficiently evaluate multiple indications under a single framework while aligning with evolving FDA guidance that supports regulatory flexibility in rare disease development.
Rare Disease Development Challenges
When asked about challenges in the company’s sector, Yang noted:
Developing therapies for rare pediatric diseases presents unique scientific, clinical, and regulatory challenges. Patient populations are small, disease progression can be rapid, and clinical endpoints must be carefully selected.
However, the regulatory landscape has evolved in ways that support innovation in rare diseases. The FDA has demonstrated increasing flexibility in clinical trial design, including openness to natural history control arms and accelerated approval pathways when supported by compelling data.
Polaryx’s strategy reflects that evolution. Through orphan drug, rare pediatric disease, and fast track designations, we are positioning the company to access regulatory incentives and potential market exclusivity, while pursuing Breakthrough Therapy Designation and accelerated approval opportunities where appropriate.
Major Company Milestones
When asked about some of the company’s most significant milestones, Yang said:
We have recently reached several key milestones that have positioned Polaryx for its next phase of growth.
We received a Safe to Proceed letter from the FDA to initiate the SOTERIA Phase 2 open-label basket trial, with launch targeted for Q4 of 2026. Enrollment is expected to begin with CLN2 and CLN3 before expanding to additional indications.
More recently, in February 2026, Polaryx completed a direct listing on Nasdaq, providing access to the public markets and enhancing our capital flexibility and visibility within the rare disease community.
Additionally, we continue to strengthen our regulatory positioning through orphan drug, rare pediatric disease, and fast track designations, while building toward future value inflection points tied to interim and final clinical readouts.
Competitive Differentiation
When asked what differentiates Polaryx from its competition, Yang emphasized:
Polaryx differentiates itself through its multimodal approach, regulatory alignment, and disciplined development strategy.
Scientifically, our platform targets both genetic drivers and downstream pathological mechanisms of lysosomal storage disorders, rather than focusing on a single pathway. Our proprietary oral small molecule approach is designed to improve patient accessibility compared to invasive treatment modalities.
Strategically, the SOTERIA basket trial allows us to pursue multiple indications efficiently under one adaptive framework. This flexible design aligns with FDA guidance and may enable accelerated development pathways if supported by data.
Finally, our leadership team and controlling shareholder bring a track record of rare disease company building and successful exits, providing both operational expertise and capital markets experience.
Future Goals
When discussing Polaryx’s future goals, Yang concluded:
Our near-term priority is initiating and advancing the SOTERIA Phase 2 basket trial in Q4 of 2026, beginning with CLN2 and CLN3 and expanding to additional indications.
Longer term, our goals include generating compelling clinical data to support Breakthrough Therapy Designation and potential accelerated approval pathways, expanding our multimodal pipeline, and increasing access to safe and effective disease-modifying treatments for children affected by lysosomal storage disorders.
Ultimately, our objective is to become a leading innovator in rare pediatric drug development, combining regulatory strategy, scientific rigor, and capital discipline to address profound unmet medical needs.
